Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAP-219 for Acute Manic Episodes in Bipolar I Disorder
NCT07046494Phase 2Completed
- Sponsor
- Rapport Therapeutics
- Start
- Jul 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RAP-219 in bipolar I disorder, sponsored by Rapport Therapeutics. Started Jul 2025; status: completed.
02
Drugs
RAP-219
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT07046494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07046494.